- Home
- GILD vs MUFG Comparison
GILD vs MUFG Comparison
Compare GILD & MUFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- MUFG
- Stock Information
- Founded
- GILD 1987
- MUFG 1880
- Country
- GILD United States
- MUFG Japan
- Employees
- GILD N/A
- MUFG N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- MUFG Commercial Banks
- Sector
- GILD Health Care
- MUFG Finance
- Exchange
- GILD Nasdaq
- MUFG Nasdaq
- Market Cap
- GILD 131.5B
- MUFG 143.3B
- IPO Year
- GILD 1992
- MUFG 2001
- Fundamental
- Price
- GILD $104.54
- MUFG $11.87
- Analyst Decision
- GILD Buy
- MUFG
- Analyst Count
- GILD 27
- MUFG 0
- Target Price
- GILD $105.32
- MUFG N/A
- AVG Volume (30 Days)
- GILD 10.4M
- MUFG 13.4M
- Earning Date
- GILD 04-24-2025
- MUFG 05-14-2025
- Dividend Yield
- GILD 3.02%
- MUFG 3.31%
- EPS Growth
- GILD N/A
- MUFG 37.26
- EPS
- GILD 0.38
- MUFG 0.96
- Revenue
- GILD $28,754,000,000.00
- MUFG $39,430,543,625.00
- Revenue This Year
- GILD $1.80
- MUFG $59.59
- Revenue Next Year
- GILD $3.83
- MUFG $0.14
- P/E Ratio
- GILD $275.11
- MUFG $12.05
- Revenue Growth
- GILD 6.04
- MUFG 69.42
- 52 Week Low
- GILD $62.07
- MUFG $8.75
- 52 Week High
- GILD $119.96
- MUFG $15.03
- Technical
- Relative Strength Index (RSI)
- GILD 43.51
- MUFG 43.89
- Support Level
- GILD $97.32
- MUFG $11.50
- Resistance Level
- GILD $107.18
- MUFG $12.04
- Average True Range (ATR)
- GILD 3.94
- MUFG 0.46
- MACD
- GILD -0.45
- MUFG -0.07
- Stochastic Oscillator
- GILD 41.42
- MUFG 44.06
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.0% share of all domestic loans as of March 2024. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.